Vnitřní lékařství 1/2020

PŘEHLEDOVÉ ČLÁNKY Autoimunitní hepatitida 18 | VNITŘNÍ LÉKAŘSTVÍ / Vnitř Lék 2020; 66(E-1): 11–18 /  www.casopisvnitrnilekarstvi.cz 43. Soares A, Cunha R, Rodrigues F, et al. Smooth muscle autoantibodies with F-actin spe- cificity. Autoimmun Rev 2009; 8: 713–716. 44. Chan Y, Tong HQ, Beggs AH, et al. Human skeletal musclespecific alpha-actinin-2 and -3 isoforms form homodimers and heterodimers in vitro and in vivo. Biochem Biophys Res Commun 1998; 248: 134–139. 45. Guéguen P, Dalekos G, Nousbaum JB, et al. Double reactivity against actin and al- pha-actinin defines a severe form of autoimmune hepatitis type 1. J Clin Immunol 2006; 26: 495–505. 46. Ballot E, Homberg JC, Johanet C. Antibodies to soluble liver antigen: an additional marker in type 1 auto-immune hepatitis. J Hepatol 2000; 33: 208–215. 47. Czaja AJ, Donaldson PT, Lohse AW. Antibodies to soluble liver antigen/liver pancreas and HLA risk factors for type 1 autoimmune hepatitis. Am J Gastroenterol 2002; 97: 413–419. 48. Czaja AJ, Carpenter HA, Manns MP. Antibodies to soluble liver antigen, P450IID6, and mitochondrial complexes in chronic hepatitis. Gastroenterology 1993; 105: 1522–1528. 49. Efe C, Ozaslan E, Wahlin S, et al. Antibodies to soluble liver antigen in patients with va- rious liver diseases: a multicentre study. Liver Int 2013; 33: 190–196. 50. Volkmann M, Luithle D, Zentgraf H, et al. SLA/LP/tRNP((Ser)Sec) antigen in autoimmu- ne hepatitis: identification of the native protein in human hepatic cell extract. J Autoim- mun 2010; 34: 59–65. 51. Wies I, Brunner S, Henninger J, et al. Identification of target antigen for SLA/LP autoan- tibodies in autoimmune hepatitis. Lancet 2000; 355: 1510–1515. 52. Terjung B, Söhne J, Lechtenberg B, et al. p-ANCAs in autoimmune liver disorders re- cognise human beta-tubulin isotype 5 and cross-react with microbial protein FtsZ. Gut 2010; 59: 808–816. 53. Terjung B, Spengler U, Sauerbruch T, et al. “Atypical p-ANCA” in IBD and hepatobiliary disorders react with a 50-kilodalton nuclear envelope protein of neutrophils and myeloid cell lines. Gastroenterology 2000; 119: 310–322. 54. Roozendaal C, de Jong MA, van den Berg AP, et al. Clinical significance of anti-neutrophil cytoplasmic antibodies (ANCA) in autoimmune liver diseases. J Hepatol 2000; 32: 734–741. 55. Czaja AJ, Pfeifer KD, Decker RH et al. Frequency and significance of antibodies to asia- loglycoprotein receptor in type 1 autoimmune hepatitis. Dig Dis Sci 1996; 41: 1733–1740. 56. Yoshioka M, Mizuno M, Morisue Y, et al. Anti-asialoglycoprotein receptor autoantibo- dies, detected by a capture-immunoassay, are associated with autoimmune liver disea- ses. Acta Med Okayama 2002; 56: 99–105. 57. Johnson PJ, McFarlane IG, McFarlane BM, et al. Autoimmune features in patients with idiopathic chronic active hepatitis who are seronegative for conventional auto-antibo- dies. J Gastroenterol Hepatol 1990; 5: 244–251. 58. McFarlane IG, Hegarty JE, McSorley CG, et al. Antibodies to liver-specific protein pre- dict outcome of treatment withdrawal in autoimmune chronic active hepatitis. Lancet 1984; 2: 954–956. 59. Roggenbuck D, Mytilinaiou MG, Lapin SV, et al. Asialoglycoprotein receptor (ASGPR): a peculiar target of liverspecific autoimmunity. Auto Immun Highlights 2012; 3: 119–125. 60. Martini E, Abuaf N, Cavalli F, et al. Antibody to liver cytosol (anti-LC1) in patients with autoimmune chronic active hepatitis type 2. Hepatology. 1988; 8: 1662–1666. 61. Abuaf N, Johanet C, Chretien P, et al. Characterization of the liver cytosol anti- gen type 1 reacting with autoantibodies in chronic active hepatitis. Hepatology 1992; 16: 892–898. 62. Czaja AJ, Shums Z, Norman GL. Nonstandard antibodies as prognostic markers in auto­ immune hepatitis. Autoimmunity 2004; 37: 195–201. 63. Renous R, Lapierre P, Djilali-Saiah I, et al. Characterization of the antigenicity of the for- miminotransferasecyclodeaminase in type 2 autoimmune hepatitis. Exp Cell Res 2004; 292: 332–341. 64. Béland K, Lapierre P, Marceau G, et al. Anti-LC1 autoantibodies in patients with chro- nic hepatitis C virus infection. J Autoimmun 2004; 22: 159–166. 65. Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Re- port: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31: 929–938. 66. Hennes EM, Zeniya M, Czaja AJ, et al. Simplified criteria for the diagnosis of autoim- mune hepatitis. Hepatology 2008; 48: 169–176. 67. Czaja AJ. Performance parameters of the diagnostic scoring systems for autoimmune hepatitis. Hepatology 2008; 48: 1540–1548. 68. Czaja AJ. Comparability of probable and definite autoimmune hepatitis by internati- onal diagnostic scoring criteria. Gastroenterology 2011; 140: 1472–1480. 69. Lamers MMH, van Oijen MGH, Pronk M, et al. Treatment options for autoimmu- ne hepatitis: a systematic review of randomized controlled trials. J Hepatol 2010; 53: 191–198. 70. EASL Clinical Practice Guidelines: autoimmune hepatitis. J Hepatol 2015; 63: 971–1004. 71. Manns MP, Woynarowski M, Kreisel W, et al. Budesonide inducesremission more effec- tively than prednisone in a controlledtrial of patients with autoimmune hepatitis. Gastro- enterology 2010; 139: 1198–1206. 72. Liberal R, de Boer YS, Andrade RJ, et al. Expert clinical man-agement of autoimmune hepatitis in the real world. Aliment Pharmacol Ther 2017; 45: 723–732. 73. Peiseler M, Liebscher T, Sebode M, et al. Efficacy and Limitations of Budesonide as a Second-Line Treatment for Patients With Autoimmune Hepatitis. Clin Gastroenterol Hepatol 2018; 16: 260–267. 74. Sandborn WJ. A review of immune modifier therapy for inflammatory bowel disea- se: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am J Gastroente- rol 1996; 91: 423–433. 75. Akbari M, Shah S, Velayos FS, et al. Systematic review and meta-analysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease. Inflamm Bowel Dis 2013; 19: 15–22. 76. Casanova MJ, Chaparro M, Domènech E, et al. Safety of thiopurines and anti-TNF-al- pha drugs during pregnancy in patients with inflammatory bowel disease. Am J Gastro- enterol 2013; 108: 433–440. 77. van Gerven NMF, Verwer BJ, Witte BI, et al. Relapse is almost universal after withdra- wal of immunosuppressive medication in patients with autoimmune hepatitis in remi- ssion. J Hepatol 2013; 58: 141–147. 78. Soloway RD, Summerskill WH, Baggenstoss AH, et al. Clinical, biochemical, and histo- logical remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology 1972; 63: 820–833.